Chronic Obstructive Pulmonary Disease YRIGHT …...Education is at the heart of patient care. A...

Education is at the heart of patient care.

A teaching hospital of Harvard Medical School

ChronicObstructivePulmonaryDiseaseGoingBeyondtheWheeze

RichardM.Schwartzstein,MD

Chief,DivisionofPulmonary,CriticalCareandSleepMedicine

EllenandMelvinGordonProfessorofMedicine

HarvardMedicalSchool

Director,ShapiroInstituteforEducationandResearch

COPYRIG

HT

A teaching hospital ofHarvard Medical School

Disclosures

• Ihavenorelationshipswithcommercialentities.• IreceivesupportfromtheNIHformyresearchondyspnea.

COPYRIG

HT


GoalsandObjectives• Todescriberecentinsightsintotheepidemiologyand

pathologyofCOPD• ToincorporateknowledgeaboutCOPDphenotypesinto

decision-makingabouttreatmentoptions• Todelineatethekeyelementsofthephysiologyofairflow

obstructioninemphysemaandtheimplicationsoftheseprinciplesforclinicalpractice

• TodetailtheessentialelementsintheevaluationofpatientswithCOPDandtohighlightcommonpitfallsintheassessmentofthesepatients

• TooutlinetherapeuticadvancesinthetreatmentofCOPD

COPYRIG

HT


COPD– Definitionincludes:• Chronicairflowobstruction• Rangeofpathologicchangesinthelung(abnormalinflammatoryresponsetonoxiousparticlesorgases)

• Extra-pulmonaryeffects• Theobstructionisprogressive• Mayhaveelementsofairwaysreactivity,i.e.,theobstructionmaybepartiallyreversible

• “Preventableandtreatable.”

COPYRIG

HT


DiagnosisofCOPD– GOLDUpdate

AJRCCM2017;195:557-582 COP

YRIGHT


COPD- Definition“…aclinicalsyndromecharacterized bychronicrespiratorysymptoms, structural abnormalities(airwaysdisease,emphysema, orboth),lung-function impairment (primarilyairflowlimitationthatispoorlyreversible)oranycombinationofthese.”

CelliB,WedzichaJA.NewEnglJMed2019;381:1257-1266.

COPYRIG

HT


COPD–oldphenotypes• Chronicbronchitis:productivecoughfor3months ineachof2consecutive years

• Emphysema: abnormalpermanentenlargementoftheairspacesdistaltotheterminalbronchioles, accompaniedbydestructionoftheirwalls,andwithoutevidenceoffibrosis

• Other:bronchiectasis, airwayreactivity

COPYRIG

HT


COPDPhenotypesareGrowing• Hersh etal.,COPD2007;4:33191patientsearlyonset,severeCOPD(FEV1<40%pred):emphysemapredominant,lowFEV1,lessbronchospasm

• Friedlanderetal.,COPD2007;4:355“Frequentexacerbater,”pulmonarycachectic,rapiddecliner,airwayshyperresponsive,impairedexercisetolerance

• Jankowich andRounds,Chest2012;141:222 (review)Combinedpulmonaryfibrosisandemphysemasyndrome;spiro maybenormal,butCTwithextensiveemphysema

COPYRIG

HT


FrequentExacerbator

2138 pts-ECLIPSE study (Eval of COPD Longitudinally to Identify Predictive Surrogate End points). Exacerbation freq in 3 yrs. Multivariate analysis. New Engl J Med 363:1128, 2010

COPYRIG

HT


COPDEPIDEMIOLOGY:StillGrowingNewEnglJMed2019;381:1257-1266

COPYRIG

HT


GOLDClassificationGlobalInitiativeforChronicObstructiveLung Disease

AmJRespCritCareMed176;532-555,2007

COPYRIG

HT


ShouldPeoplebeScreened forCOPDwithSpiro?• Linetal.,AnnIntMed2008;148:535

– USPreventativeServicesTaskForce– Metaanalysis- couldyoupreventCOPDexacerbations?Reducemorbidityandmortality?Enhancesmokingcessation?

– Screen833ptstoprevent1COPDexacerbation– NodatatosuggestdecreaseM&M– Nodatatosupportenhancedsmokingcessation

• Note:FEV1/FVCratiodeclineswithnormalaging• Controversyabout“smalllungs”ingrowthanddevelopment

COPYRIG

HT


LungSizeatBirth:DiagnosisofCOPDNewEnglJMed2019:381;1248-1256

COPYRIG

HT


RateofHospitalizationforCOPD(comparedtoCAD)PersistsDespite

DecreaseinSmoking

Likely related to aging population.AJRCCM 2017;195:287-291.

COPYRIG

HT


COPDMortality• “Chroniclowerrespiratorydisease”nowthethirdleadingcauseofdeathintheUS.

• Numberofwomendying>men(studiessuggestwomenmaybemoresusceptibletocigs:Silvermanetal.AJRCCM2000;162:2152)

• Onlydiseaseintop10à mortality increasing.• Evensmokers<1ppdhaveé mortalitycomparedtonon-smokers Inoue-Choietal.JAMAIntMed2017

COPYRIG

HT


COPD- CausesofDeathpulm>cardiovasc>cancer NEJM356;851854,2007

COPYRIG

HT


COPD- RiskFactors• Cigarettes- activeandpassivesmoking(30-50%ofcurrent/formersmokershaveairflowobstruction)

• Airwaysreactivity:“DutchHypothesis”– commonlinksbetweenCOPDandasthma

• Geneticsusceptibility– alpha1anti- trypsindeficiency– Othergenesmayexplainvariabilityinriskwithsmoking

• Bacterial,viralinfections;cigsmokereducesimmuneresponse– interferon,IL-1(Chest143:196,2013)

• Airpollutionandoccupationalexposures

COPYRIG

HT


SmokingasRisk:duration>intensity

Smokingdurationgreaterriskforemphysemathancigarettesperday

Thorax 2018;73:414-421

COPYRIG

HT


DutchHypothesis• Firstproposedin1961• Threeprinciples

– VariousformsofCOPDhaveoverlappingfeatures– Oneformofobstructivelungdisease(asthma)mayevolveintoanother(COPD)

– Developmentofobstructivelungdiseaseresultofcombinationof:1)inflammationandairwayreactivity2)geneticpredisposition3)environmentalfactors

COPYRIG

HT


Asthma-COPDOverlapSyndrome(ACOS)

Chest 2019;155:168-177Estimated present in 15-45% of people with obstructive lung disease

COPYRIG

HT


Emphysema(lungsmorecompliant)inNonsmokingAsthmaPatients

Chest 2018;153;6118-629

COPYRIG

HT


GeneticRiskFactors• Alpha1anti-trypsin• 30-50%oflungfunctionmaybedeterminedbygenetics;susceptibilitytoCOPDlikelypolygenic.Familystudies:SiblingsofCOPDpatientsincreasedrisk

AmJRespirCritCareMed164:1419, 2001• Genesactivatedbysmokingmayleadtodisease(Chest133:1344, 2008)OR maybeprotective(protectivegenesinpromoterregionMMP12associatedwithhigherFEV1,reducedriskofCOPD-NewEnglJMed361:2599,2009)

COPYRIG

HT


GeneticsandDiseaseInsights• COPDGeneStudy

– Analysisof2500peopleofAfricanandEuropeanancestry;multivariatelogisticregressionmodeling

– African-Americansmorelikelytohaveearlyonsetdisease

AmJRespirCritCareMed2011;184:414-420• GeneticsandCOPDphenotypes

– 12,031subjects– Fivelociidentifiedwithemphysemarelatedphenotypes,onewithairway,twowithgastrapping

AmJRespirCritCareMed2015;192:559-569

COPYRIG

HT


Smoking® Inflammation• Inflammation- increasedneutrophilsinmucosa;increasedCD-8cellsinsubepithelium.

MaestrelliP.AmJRespirCritCareMed2001

• LVHmorecommoninCOPDpts(evenwithnormalO2levels)withouthxofhypertensionc/wcontrols

Andersonetal.Chest143:91,2013

• Datafeedscontroversyaboutsteroidsandanti-oxidants

COPYRIG

HT


PresenceofIL-17AinLungTissueandSeverityofDiseaseAmJRespirCritCareMed2016:193:1092-1100

COPYRIG

HT


Mepolizumab– AntibodytoInterleukin5• Phase3trial;

randomized,placebo,doubleblinded

• 462patients;eosinophilicphenotype(eos150-300/ml);highdoseICS

• Reducedcumulativeexacerbationsover52weekswhenaddedtosteroids

COPYRIG

HT


MuscleDysfunctioninCOPDSystemiccatabolicstate?

Am J Respir Crit Care Med 2015;191:616COP

YRIGHT


MuscleDysfunctioninCOPDAm J Resp Crit Care Med2018;198;175-186

COPYRIG

HT


COPDPhysiology

• Lossofelasticrecoil• Airwaysobstruction- the‘equalpressurepoint’

• Hyperinflation• AutoPEEPCOPYRIG

HT


LungParenchymasupportsAirwaysSchwartzsteinRM,ParkerMJ,RespiratoryPhysiology2005

COPYRIG

HT


Hyperinflation

• Shorteningofmusclesleadstoamechanicaldisadvantageintheattempttogeneratenegativeintra-pleuralpressure

• Contributestothedevelopmentofventilatorymusclefatigue

• Maystimulatechestwallreceptorscontributingtodyspnea

COPYRIG

HT


Auto-PEEP

• Persistenceofpositivepressureintheairwaysattheendofexhalation

• Associatedwithhyperinflation• Resultsinanadditionalburdenduringinspiration- a‘thresholdinspiratoryload’COPYRIG

HT


AutoPEEP• AutoPEEPaccompaniesexpiratoryflowlimitation

• Heterogeneouslungunitswithvariabletimeconstants(TC=RXC)

• Contributestoworkofbreathing,dyspnea

Marini,AJRCCM2011;184:756

COPYRIG

HT


Dyspnea:Morethanyouthought…• Basicphysiologyofdyspnea iscomplex- manyfactorscontributetorespiratorydiscomfort

• Thequalitiesofrespiratorydiscomfort vary;mayprovideinsightintotheetiologyofthedyspnea

• Levelofdyspneamore closelycorrelatedwith5-yearsurvival thanFEV1(Chest121:1434, 2002)

• Dailyphysicalactivity isindependentpredictorformortalityandhospitalizationduetoexacerbation (Chest142:338, 2012;andThorax67:117,2012)

COPYRIG

HT


DescriptorsofDyspnea• Mybreathdoesnotgoinall

theway• Mybreathingrequireseffort• IfeelthatIamsmothering• I feelahungerformoreair• Mybreathingisheavy• Icannottakeadeepbreath• Ifeeloutofbreath• Mychestfeelstight• Mybreathingrequiresmore

work

• IfeelthatIamsuffocating• Ifeelthatmybreathstops• Iamgaspingforbreath• Mychestisconstricted• Mybreathingisrapid• Mybreathingisshallow• IfeelthatIambreathingmore• Icannotgetenoughair• Mybreathdoesnotgooutall

theway

COPYRIG

HT


PhysiologyofDyspnea• ‘Tightness, constriction’ - bronchospasm• ‘Urgetobreathe,airhunger’- increasedrespiratorydrive:e.g.,CO2,severeasthma, CHF

• ‘Effortofworkofbreathing’ - increasedmechanical impedance

• ‘Unsatisfied inspiratory effort’ - hyperinflation• ‘Heavybreathing, breathingmore’-deconditioning

COPYRIG

HT


PulmonaryFunctionTests• Spirometry - maybemoreconsistent inCOPDthanarepeakflows

• Lungvolumes- airtrapping, hyperinflation;bewareofimpactofbullousdiseaseonheliumdilutionmeasurements oflungvolumes

• Diffusingcapacity- predictiveofdesaturation• Flowvolume loop- mayhelpdistinguish“pure”emphysemaandasthma

COPYRIG

HT


PFT’sinCOPD

COPYRIG

HT


Flow-volumeCurveinCOPD

COPYRIG

HT


Oximetry• Assessoxygenationatrest• Desaturationonexercise(correlatewithlowdiffusingcapacityPFT’s)

• Considernocturnaloximetryifevidenceofrightheartfailureorpolycythemia

• Increasingdataonroleofpulmonaryhypertensionasfactorindecreasedexercisecapacity

COPYRIG

HT


It’sNeverTooLateToStopSmokingSchwartzsteinRM

Smokers lose one decade of life expectancy; stop by age 40, reduces risk by 90%NEJM 368:4, 2013

COPYRIG

HT


SmokingCessation:Multi-prongedApproach• Behavioral(telephoneandgroupcounseling)andpharmacotherapyinterventionscombinedbestresults

• PatnodeCDetal.AnnIntMed,2015-- ReviewofreviewsforUSPreventiveServicesTaskForce– Behavioralinterventions(phone,counseling,etc.)pluspharmacotherapy1.76oddsratioofsuccesscomparedtousualcare

– Nicotinereplacement,buproprionandvareniclinealleffective(vareniclinemosteffective)

• Quitesmokingà reducedriskofdementia(Choietal.AnnClinandTranslationalNeuro2018)

COPYRIG

HT


ElectronicCigarettesNEJM2016;375:1372-1381

• Batteryoperated,nicotinedeliverydevices;producevaporwithnicotineandpropyleneglycolorglycerol

• 18%quitsmokingwithe-Cigsinrandomizedtrialc/w10%incontrol(standardnicotinereplacement;lowersuccessratethanmoststudies)(NEJM2019;380:629)

• 1/3ofusershaveneversmokedcigarettes;vapormaycontainformaldehydeandothercarcinogensà recentmini-epidemicofacutelungreactionsanddeaths(NEJMSeptember6,2019- epub)

• Nicotinemaybe“gatewaydrug;”associatedwithotherdrugabuse(NEJM2014;371:932);particularproblemforadolescentssusceptibletoaddiction(AnnIntMed2015;163:59-60)

COPYRIG

HT


E-CigarettesandSmokingCessation• Supplementaryuseofe-cigsforpatientsbeingdischargedfromhospitalwithgoalofsmokingcessationà lessabstinencefromsmokingat6months(Rigottietal.,AnnIntMed2018)

• PopulationstudyinEurope;cross-sectionallogisticalregressionofassociationofe-cigsandbeingformersmokerà e-cigsassociatedwithloweroddsofbeingaformersmoker(Kuliketal.,AmJPrevMed2018;54:603-609)

COPYRIG

HT


BronchodilatorsinCOPDInspirationorExpiration?

• Taubeetal.AJRCCM162:216,2000

– Betaagonists:∆FIV1(inspiratoryflow!)bestpredictorofdecreaseddyspnea;∆ICalsobetterthanFEV1.

• O’Donnelletal.EurRespirJ.18:914,2002

– Postsalbutamol,83%ofpatientsimprovedlungvolumemeasurements,i.e.,lesshyperinflation,inabsenceof∆FEV1

• Cellietal.Chest124:1743,2003

— TiotropiumincreasedICmorethanFEV1

COPYRIG

HT


GoalsofTherapyinCOPD?• FEV1– severity• ChangeinFEV1–progression

• Exacerbations–activity

• Qualityoflife,symptoms– Impactonpatient

• Future:biomarkers;diseaseactivity Am J Resp Crit Care Med 2016;194:541-549

COPYRIG

HT


GoalsofTherapyinCOPDEvolving

Am J Resp Crit Care Med 2016;194:541-549COPYRIG

HT


LABA+LAMAvs.LABA+ICSNEJM2016;374:2222-2234

• Indacterol+GlycopyrroniumvsSalmeterol+Fluticasone

• 11%reductioninannualrateofCOPDexacerbationwithoutsteroids

• Absoluteratereduction:4.03to3.59

Time to First Exacerbation

COPYRIG

HT


WithdrawalofInhaledSteroidsDecreasesPFTsNEJM2014;371:1285

• 2485pts,hxofCOPDexacerbation;tio+salmeterol+ICS

• RandomlyassignedtostopICSover12weeks

• NodiffinexacerbationsbutgreaterdeclineinFEV1withstopinICS

AJRCCM2017;195:1189

• ↑bloodeos→↑riskexacerbationpoststoppingICS

COPYRIG

HT


De-escalationofTripleTherapyandIncreasedExacerbations:Assoc.WithEosOverall,smalldecreaseinFEV1withnodiff.inexacerbations.HigherexacerbationriskandfallFEV1inpts.with> 300bloodeos/microliter

Am J Resp Crit Care Med 2018;198;329-339

COPYRIG

HT


GOLDSummaryonBronchodilators

COPYRIG

HT


Corticosteroids• Approximately1/3ofpatientswillrespondtosteroidswithimprovedlungfunction

• Cannotpredictwhichpatientswillrespondbasedonpreandpostbronchodilatorchallengewithbetaagonist

• SmallchangesinFEV1maymakebigchangesindyspnea

• Increasingevidenceonroleofbloodeosinophilsasmarkerforresponsiveness

COPYRIG

HT


PneumoniaandMortalityinCOPD• LimitsofstudiesofpneumoniainCOPDandICS

– Riskofbias– Lackofsystematicascertainmentofpneumonia;dependenceonadverseriskreporting

– Retrospective,observationalstudydesigns

• Noevidenceofincreasedmortality• Possible“double-effect”– anadverseeffectplusanunexplainedmitigatingeffect;ICSmayimprovemortality

AmJRespirCritCareMed2015;191:141-148

COPYRIG

HT


InhaledSteroidsandPneumonia• CochraneDatabaseSystematicReview2014

– Randomizedcontrolledstudies;atleast12weeksduration

– BudesonideorFluticasonevs.placebowith/withoutLABA

– ICSincreasednon-fatalseriousadversepneumoniaevents,i.e.,requirehospitaladmission

– Nodifferenceinoverallmortalityrates

COPYRIG

HT


ICSAssociatedwithLowerRiskofHospitalizationinOlderPtswithCOPD

Retrospective longitudinal population cohort age > 66 with COPD in Canada.Exposure = new receipt of ICS.Y-axis = proportion free of hospitalization.AnnalsATS 2019;16:1252-1262

ICS

No ICSCOPYRIG

HT


InhaledSteroidsandRiskofTBandFlu

• Systematicreview;randomized,controlledtrials– 25forTB(showningraph),26forinfluenza

• HigherriskforTB(butfewevents);nodifferenceforflu

Chest 2014;145:1286

COPYRIG

HT


ProphylacticAntibioticsandCOPDExacerbations

• CochraneReview2013• SevenRCTs;studiesinvolvedmacrolideseithercontinuousorintermittent;duration3to36months

• Results:numberofpatientsexperiencingexacerbationsreducedfrom69to54%;statisticallybutnotclinicallysignificant↑QOL

• Nomajorproblemswithresistantorganisms

COPYRIG

HT


Azithromycinfor3monthsforHospitalizedCOPDExacerbations

• Randomized,double-blinded,placebocontrolled• PatientshospitalizedforCOPDexacerbation;randomizedwithin48hourstoazithromycinvsplacebofor3months(addedtostandardtreatmentwithsteroidsandin-hospitalantibiotics).

• Followedfor6months;treatmentfailure(increaseinmedsorhospitalization)was49%intreatmentgroup;60%inplacebo

Vermeersch K,etal.AmJRespir Crit CareMed- October2019- epub

COPYRIG

HT


COPDReadmissions– onlyhalfduetoRespiratoryillness

• 26millionadmits• 3.5%COPD• 20.2%readmitin30days;onlyhalfduetorespillness

• Dualmedicare–medicaidhigherrisk

Chest 2015;147:1219

COPYRIG

HT


KeyPointsonAnti-Inflammatories

COPYRIG

HT


OxygenTherapy- IndicationsChest 138:179, 2010

Note: use of O2 for sats 89-93 with mild exercise desat–no mortality benefitNEJM 2016;375:1617.

COPYRIG

HT


OxygenandMortality• COT– continuousoxygentherapy(24hrs/day)

• MRC– MedicalResearchCouncil(15hrs/day)

• NOT– nocturnaloxygentrial

Chest138:179,2010

COPYRIG

HT


Roflumilast– Phosphodiesterate4Inhibitor• Anti-inflammatoryagent• 2placebo-controlled,multi-

centertrials;note:inhaledsteroidsstopped

• 3091pts,overage40,FEV1<50%predicted

• Roflumilast500mcg/day• Exacerbationsreduced1.37

to1.14(p<0.003)• FEV1increased48ml

• Calverleyetal.Lancet2009;374:686

Roflumilast reduced frequency of exacerbations in severe COPD patients with freq exacerbator phenotype. Wedzicha et al.Chest 143:1302, 2013; Martinez et al. AJRCCM 2016;194:559-567

Eos > 150 predictor of effect as wellAJRCC 2018;1268

COPYRIG

HT


COPDandPrognosisThe“BODE”Index

• MultidimensionalgradingsystemthatincorporatesrespiratoryandsystemicexpressionsofCOPDüBody-massindex(B)üAirflowobstruction(O)üDyspnea(D)üExercisecapacity(E)

• HigherBODEscore® greaterriskofhospitalizationanddeathCellietal.NEnglJMed350:1105,2004Ongetal.Chest128:3810,2005

COPYRIG

HT


NutritionandCOPD• Bodyweighthasindependenteffectonsurvival• Thresholdvalueof25kg/m2 belowwhichmortalityriskincreased

• Possibleroleofsystemicinflammation;notmalnutritionperse.Increasedmarkersofcatabolism,e.g.,IL-6DebigareRetal.Chest124:83,2003

• Inunderweightpatient,unclearweightgainenhancessurvival

• VitDinptswithlowlevelsmayreduceexacerbationsLehoucketal.AnnIntMed156:105,2012

COPYRIG

HT


Exercise

COPYRIG

HT


PulmonaryRehabilitation• Importanceofdeconditioningasalimitingfactorinmany

patientswithCOPD;• Mechanismofeffectprobablyvarieswithpatient:

1)reconditioning;2)moreefficientuseofbreathingmuscles;3)strengtheningofbreathingmuscles;4)desensitizationtodyspnea

• Upto14%ofptswithCOPDstopexercisingduetolegdiscomfort(FEV144%pred.)Chest144:491,2013

• Patientsreporting“moderateorvigorousphysicalactivity”eachweek,significantreductioninreadmitrateafterexacerbationAnnAmThorSoc11:695;2014

COPYRIG

HT


PulmonaryRehab• Riesetal.,AnnIntMed1995A)IncreasedtreadmillenduranceB)DecreaseddyspneaC)Decreasedmusclefatigue

-- Effectslastedfor12monthsoffollow-up

A

B

CCOPYRIG

HT


MaintenanceRehabforTwoYears

Afterinitialrehabprogram,groupsrandomizedtorepeatvisitsq2weeksvs.controlworkingontheirown.Maintained6MWDbetterwithsupervision.BaselineFEV1<40%predicted.AJRCCM2017;195:622-629

COPYRIG

HT


PulmonaryRehab- EfficacyCochraneDatabase; systematicreview2015;February 23

• 65RCT’sreviewed;3822participants• MeanFEV139%predicted• Statistically significant improvement inQOLoutcomes

• Significant increase in6MWTdistance

COPYRIG

HT


COPDExacerbations

COPYRIG

HT


VolumeReductionSurgery• Physiologicprinciples:A)reducethehyperinflationofthechest;B)allowmorenormalportionsofthelungtoexpandandreceivegreaterventilation/perfusion

• Appeartobefewercomplicationswiththoracoscopic vsmediansternotomyapproach

• Improvement inQOLmeasures, eg.,physicalandsocialfunctioning, vitality (Chest115:383, 1999)

COPYRIG

HT


NETTStudySubgroupAnalysis

• PredominantlyUpperLobeEmphysemaand LowExerciseCapacity– Mortalitylowerinsurgeryvsmedicaltherapy(p=0.005)

• Non-upperLobeEmphysemaand HighExerciseCapacity– Mortalityhigherinsurgerythanmedicalgroup(p=0.02)

COPYRIG

HT


EndobronchialValvesandCoilsHomogeneousemphysema;nocollateralvent;93patients;randomized

• SignificantbutmarginalabsolutechangeinFEV1

• Improvedqualityoflifeat3months

AmJRespir Crit CareMed194:1073,2016

Endocoilscompressemphysematouslung•315pts;bilateralcoils•↑6MWD(10mvslossof7.6m)•ImprovedQOLmeasures•Complications34.8%vs19.1%incontrolJAMA2016;315;2178

COPYRIG

HT


LungTransplantation

• Singlelungtransplantationissuccessfuldespitetheverycompliantnatureofthelungleftbehind

• Longwaitfordonororgan• Survivalstill50%atfouryearsCOPYRIG

HT


GOLDSummaryforAdvancedCOPD

COPYRIG

HT


COPDSummary• COPDassociatedwithvaryingphenotypes;roleofinflammationleadstotherapeuticstrategies

• Elasticrecoilkeytophysiologyofemphysema• SmallchangesinFEV1andlungvolumesmayresultinbigchangesindyspnea;hyperinflationmajorconsequenceofobstruction

• FunctionallimitmaynotbefromCOPD;considerrehab• HypoxicpatientsneedsupplementalO2

• Increasinglylinktreatmenttophenotype,impactonpatient

COPYRIG

HT

Chronic Obstructive Pulmonary Disease YRIGHT …...Education is at the heart of patient care. A...

Documents

Transcript of Chronic Obstructive Pulmonary Disease YRIGHT …...Education is at the heart of patient care. A...